Ofori-Asenso Richard, Chin Ken Lee, Sahle Berhe W, Mazidi Mohsen, Zullo Andrew R, Liew Danny
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3181, Australia.
Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 2 2300 Universitetsparken, Copenhagen, Denmark.
Geriatrics (Basel). 2020 Mar 12;5(1):17. doi: 10.3390/geriatrics5010017.
We performed an overview of systematic reviews and meta-analyses to summarize available data regarding the association between frailty and all-cause mortality. Medline, Embase, CINAHL, Web of Science, PsycINFO, and AMED (Allied and Complementary Medicine) databases were searched until February 2020 for meta-analyses examining the association between frailty and all-cause mortality. The AMSTAR2 checklist was used to evaluate methodological quality. Frailty exposure and the risk of all-cause mortality (hazard ratio [HR] or relative risk [RR]) were displayed in forest plots. We included 25 meta-analyses that pooled data from between 3 and 20 studies. The number of participants included in these meta-analyses ranged between <2000 and >500,000. Overall, 56%, 32%, and 12% of studies were rated as of moderate, low, and critically low quality, respectively. Frailty was associated with increased risk of all-cause mortality in 24/24 studies where the HR/RRs ranged from 1.35 [95% confidence interval (CI) 1.05-1.74] (patients with diabetes) to 7.95 [95% CI 4.88-12.96] (hospitalized patients). The median HR/RR across different meta-analyses was 1.98 (interquartile range 1.65-2.67). Pre-frailty was associated with a significantly increased risk of all-cause mortality in 7/7 studies with the HR/RR ranging from 1.09 to 3.65 (median 1.51, IQR 1.38-1.73). These data suggest that interventions to prevent frailty and pre-frailty are needed.
我们进行了系统评价和荟萃分析的概述,以总结关于衰弱与全因死亡率之间关联的现有数据。检索了Medline、Embase、CINAHL、Web of Science、PsycINFO和AMED(补充与替代医学)数据库,直至2020年2月,以查找检验衰弱与全因死亡率之间关联的荟萃分析。使用AMSTAR2清单评估方法学质量。在森林图中展示了衰弱暴露和全因死亡率风险(风险比[HR]或相对风险[RR])。我们纳入了25项荟萃分析,这些分析汇总了3至20项研究的数据。这些荟萃分析纳入的参与者数量在<2000至>500,000之间。总体而言,分别有56%、32%和12%的研究被评为中等、低和极低质量。在24/24项研究中,衰弱与全因死亡率风险增加相关,其中HR/RR范围从1.35[95%置信区间(CI)1.05 - 1.74](糖尿病患者)至7.95[95%CI 4.88 - 12.96](住院患者)。不同荟萃分析的HR/RR中位数为1.98(四分位间距1.65 - 2.67)。在7/7项研究中,衰弱前期与全因死亡率风险显著增加相关,HR/RR范围从1.09至3.65(中位数1.51,四分位间距1.38 - 1.73)。这些数据表明需要采取干预措施来预防衰弱和衰弱前期。